 The TARGET-DLE trial will address these problems by: i administering a TNF blocker, etanercept using the intra-dermal route, which will provide local concentration to neutralise TNF in tissue while minimises the effect to systemic immunity and ii measuring tissue response using the existing outcome measure; the modified limited Score of Activity and Damage in DLE SADDLE as well as new objective measures such as skin biopsy, optical coherence tomography OCT, thermography and laser Doppler imaging LDI. 